Skip to main content

Table 1 Clinical characteristics of the study population (n = 826)

From: Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis

Characteristicn (%)
Median age, years (IQR)62 (52–70)
Male sex524 (63.4)
Non-Hispanic white704 (85.2)
Comorbidities408 (49.4)
Smoking390 (47.2)
Cancer type
 Melanoma347 (42.0)
 Solid tumor363 (43.9)
 Hematologic116 (14.0)
Cancer stage (n = 709)
 III85 (12.0)
 IV624 (88.0)
ICI type
 Anti-CTLA-4264 (32.0)
 Anti-PD-1/L1426 (51.6)
 Combination136 (16.5)
Median duration of ICI therapy, days (IQR)56 (22–116)
IMDC434 (52.5)
Median time to IMDC onset, weeks (IQR)8 (4–15)
Median duration of IMDC symptoms, days (IQR)9 (3–20)
Grade of colitis (n = 319)
 174 (23.2)
 2150 (47.0)
 384 (26.3)
 411 (3.4)
Grade of diarrhea (n = 434)
 1129 (29.7)
 2120 (27.6)
 3164 (37.8)
 421 (4.8)
Treatment of IMDC (n = 434)
 Immunosuppressants276 (63.6)
 Symptomatic only158 (36.4)
Infliximab and/or vedolizumab add-on83 (10.0)
Antibiotic therapy
 No257 (31.1)
 Yes569 (68.9)
  Before ICI therapy only186 (32.7)
  After ICI therapy and before IMDC onset84 (14.8)
  Both299 (52.5)
 Use of antibiotics with antianaerobic activity288 (50.6)
Recurrence of IMDC83 (10.0)
Colon perforation7 (1.0)
Nongastrointestinal irAEs312 (37.8)